logo
Plus   Neg
Share
Email

Kiniksa Pharma: KPL-716 Phase 1a/1b Achieves Its Study Goals

Kiniksa Pharmaceuticals, Ltd. (KNSA) presented Phase 1a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta. In the First-in-Human clinical trial, single intravenous and subcutaneous doses of KPL-716 were well-tolerated in both adult healthy volunteers and adult subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. KPL-716 also demonstrated a reduction in pruritus. The company said the results support its plans for expanding clinical development into multiple chronic pruritic diseases, including prurigo nodularis.

"Data from the single-dose cohorts of the placebo-controlled Phase 1a/1b of KPL-716 achieved the goals established for the study. The results provided us with data on the safety and tolerability of KPL-716 as well as the anti-pruritic effect of the drug," said Sanj Patel, CEO and Chairman of the Board of Kiniksa.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Inc. (WMT) reported adjusted EPS of $1.41 for the fourth-quarter of fiscal 2019. On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $1.33 for the quarter. Analysts' estimates typically exclude special items. Net income attributable to Walmart... Anglo-Australian miner BHP, formerly known as BHP Billiton, reported Tuesday higher attributable profit in its first half, while revenues were flat. Underlying EBITDA margin was lower. Further, the company maintained its dividend. Looking ahead, the company said its productivity for the 2019 financial year is now expected to be broadly flat. Asia-focused lender HSBC Holdings Plc reported Tuesday higher profit in its fiscal 2018 reflecting revenue growth in all of global businesses, despite a challenging fourth quarter. Further, the company said it reported a good start to 2019, noting that Group revenue performance in January was ahead of plan for the month. In London, HSBC shares were losing around 4 percent in the morning trading.
Follow RTT